TD Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

TD Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-52,200	Closed	-$939K	–	1399
2015 Q1	$939K	Buy	52,200 +4,300	+9%	+$67.3K	﹤0.01%	959
2014 Q4	$821K	Buy	47,900 +30,100	+169%	+$430K	﹤0.01%	977
2014 Q3	$255K	Buy	+17,800	New	+$256K	﹤0.01%	1193

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

TD Asset Management's AVDL Position: Q2 2015 in Review

TD Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2015, closing a stake of 52,200 shares — an estimated $939K sold.

TD Asset Management first reported a position in AVDL in Q3 2014 and held it in 3 quarters. The position peaked at $939K in Q1 2015. 87 funds tracked by Wall St. Rank hold AVDL as of Q2 2015.

TD Asset Management reported no remaining Avadel Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
TD Asset Management sold 52,200 Avadel Pharmaceuticals shares in Q2 2015, an estimated $939K.
TD Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 3 quarters.
TD Asset Management's Avadel Pharmaceuticals position peaked at $939K in Q1 2015.
87 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2015.

Based on TD Asset Management's 13F filing for Q2 2015, filed 11 Aug 2015.